Does the media refer more to AVTX or AKBA?

In the previous week, Avalo Therapeutics had 14 more articles in the media than Akebia Therapeutics. MarketBeat recorded 19 mentions for Avalo Therapeutics and 5 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.18 beat Avalo Therapeutics' score of -0.10 indicating that Akebia Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Akebia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer AKBA or SANA?

In the previous week, Sana Biotechnology had 14 more articles in the media than Akebia Therapeutics. MarketBeat recorded 19 mentions for Sana Biotechnology and 5 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.18 beat Sana Biotechnology's score of 0.05 indicating that Akebia Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Sana Biotechnology 1 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to JANX or AKBA?

In the previous week, Janux Therapeutics had 16 more articles in the media than Akebia Therapeutics. MarketBeat recorded 21 mentions for Janux Therapeutics and 5 mentions for Akebia Therapeutics. Janux Therapeutics' average media sentiment score of 0.47 beat Akebia Therapeutics' score of 0.18 indicating that Janux Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Janux Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Akebia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Is AKBA or OMER more profitable?

Omeros has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. Akebia Therapeutics' return on equity of -88.88% beat Omeros' return on equity. Company Net Margins Return on Equity Return on Assets Akebia Therapeutics -13.54% -88.88% -7.74% Omeros N/A -164.92% 69.41%

Does the media prefer AKBA or OMER?

In the previous week, Omeros had 28 more articles in the media than Akebia Therapeutics. MarketBeat recorded 33 mentions for Omeros and 5 mentions for Akebia Therapeutics. Omeros' average media sentiment score of 0.52 beat Akebia Therapeutics' score of 0.18 indicating that Omeros is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Omeros 6 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AKBA or GERN?

In the previous week, Geron had 1 more articles in the media than Akebia Therapeutics. MarketBeat recorded 6 mentions for Geron and 5 mentions for Akebia Therapeutics. Geron's average media sentiment score of 0.72 beat Akebia Therapeutics' score of 0.18 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Akebia Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Geron 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Akebia Therapeutics (AKBA) Competitors

$0.88 +0.01 (+1.70%)

Closing price 08/14/2026 04:00 PM Eastern

Extended Trading

$0.88 -0.01 (-0.95%)

As of 08/14/2026 07:55 PM Eastern

Compare

AKBA vs. AVTX, SANA, JANX, OMER, and GERN

Should you buy Akebia Therapeutics stock or one of its competitors? Akebia Therapeutics's main competitors and comparable companies include Avalo Therapeutics (AVTX), Sana Biotechnology (SANA), Janux Therapeutics (JANX), Omeros (OMER), and Geron (GERN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Akebia Therapeutics compare to Avalo Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

Avalo Therapeutics currently has a consensus target price of $45.10, indicating a potential upside of 130.22%. Akebia Therapeutics has a consensus target price of $3.75, indicating a potential upside of 324.02%. Given Akebia Therapeutics' higher probable upside, analysts clearly believe Akebia Therapeutics is more favorable than Avalo Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Avalo Therapeutics had 14 more articles in the media than Akebia Therapeutics. MarketBeat recorded 19 mentions for Avalo Therapeutics and 5 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.18 beat Avalo Therapeutics' score of -0.10 indicating that Akebia Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Avalo Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Akebia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Avalo Therapeutics has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market.

Avalo Therapeutics has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. Avalo Therapeutics' return on equity of -58.03% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Akebia Therapeutics	-13.54%	-88.88%	-7.74%

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by company insiders. Comparatively, 4.3% of Akebia Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Akebia Therapeutics has higher revenue and earnings than Avalo Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Avalo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	17,510.20	-$78.26M	-$4.37	N/A
Akebia Therapeutics	$236.20M	1.04	-$5.34M	-$0.11	N/A

Summary

Avalo Therapeutics beats Akebia Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Akebia Therapeutics compare to Sana Biotechnology?

Akebia Therapeutics (NASDAQ:AKBA) and Sana Biotechnology (NASDAQ:SANA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership, media sentiment and valuation.

In the previous week, Sana Biotechnology had 14 more articles in the media than Akebia Therapeutics. MarketBeat recorded 19 mentions for Sana Biotechnology and 5 mentions for Akebia Therapeutics. Akebia Therapeutics' average media sentiment score of 0.18 beat Sana Biotechnology's score of 0.05 indicating that Akebia Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akebia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Sana Biotechnology	1 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Akebia Therapeutics has higher revenue and earnings than Sana Biotechnology. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20M	1.04	-$5.34M	-$0.11	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A

Sana Biotechnology has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. Akebia Therapeutics' return on equity of -88.88% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-13.54%	-88.88%	-7.74%
Sana Biotechnology	N/A	-103.02%	-39.16%

Akebia Therapeutics presently has a consensus price target of $3.75, indicating a potential upside of 324.02%. Sana Biotechnology has a consensus price target of $9.33, indicating a potential upside of 162.91%. Given Akebia Therapeutics' higher possible upside, research analysts plainly believe Akebia Therapeutics is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Akebia Therapeutics has a beta of 0.26, suggesting that its share price is 74% less volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.16, suggesting that its share price is 116% more volatile than the broader market.

33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 4.3% of Akebia Therapeutics shares are owned by insiders. Comparatively, 25.4% of Sana Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Sana Biotechnology beats Akebia Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Akebia Therapeutics compare to Janux Therapeutics?

Janux Therapeutics (NASDAQ:JANX) and Akebia Therapeutics (NASDAQ:AKBA) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, profitability, earnings, dividends, media sentiment, valuation, risk and institutional ownership.

Janux Therapeutics presently has a consensus target price of $37.58, suggesting a potential upside of 133.15%. Akebia Therapeutics has a consensus target price of $3.75, suggesting a potential upside of 324.02%. Given Akebia Therapeutics' higher possible upside, analysts clearly believe Akebia Therapeutics is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Janux Therapeutics	2 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.50
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Janux Therapeutics has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. Janux Therapeutics' return on equity of -11.89% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Janux Therapeutics	N/A	-11.89%	-11.13%
Akebia Therapeutics	-13.54%	-88.88%	-7.74%

75.4% of Janux Therapeutics shares are held by institutional investors. Comparatively, 33.9% of Akebia Therapeutics shares are held by institutional investors. 7.9% of Janux Therapeutics shares are held by insiders. Comparatively, 4.3% of Akebia Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Akebia Therapeutics has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Janux Therapeutics	$24M	41.06	-$113.62M	-$1.64	N/A
Akebia Therapeutics	$236.20M	1.04	-$5.34M	-$0.11	N/A

In the previous week, Janux Therapeutics had 16 more articles in the media than Akebia Therapeutics. MarketBeat recorded 21 mentions for Janux Therapeutics and 5 mentions for Akebia Therapeutics. Janux Therapeutics' average media sentiment score of 0.47 beat Akebia Therapeutics' score of 0.18 indicating that Janux Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Janux Therapeutics	2 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Akebia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

Janux Therapeutics has a beta of 2.5, indicating that its stock price is 150% more volatile than the broader market. Comparatively, Akebia Therapeutics has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market.

Summary

Janux Therapeutics beats Akebia Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Akebia Therapeutics compare to Omeros?

Akebia Therapeutics (NASDAQ:AKBA) and Omeros (NASDAQ:OMER) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk.

In the previous week, Omeros had 28 more articles in the media than Akebia Therapeutics. MarketBeat recorded 33 mentions for Omeros and 5 mentions for Akebia Therapeutics. Omeros' average media sentiment score of 0.52 beat Akebia Therapeutics' score of 0.18 indicating that Omeros is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akebia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Omeros	6 Very Positive mention(s)	3 Positive mention(s)	12 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Omeros has lower revenue, but higher earnings than Akebia Therapeutics. Akebia Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20M	1.04	-$5.34M	-$0.11	N/A
Omeros	N/A	N/A	-$3.35M	$1.28	13.43

Akebia Therapeutics presently has a consensus target price of $3.75, suggesting a potential upside of 324.02%. Omeros has a consensus target price of $38.00, suggesting a potential upside of 121.06%. Given Akebia Therapeutics' higher possible upside, analysts plainly believe Akebia Therapeutics is more favorable than Omeros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Omeros	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67

33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 4.3% of Akebia Therapeutics shares are owned by insiders. Comparatively, 10.5% of Omeros shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Akebia Therapeutics has a beta of 0.26, meaning that its share price is 74% less volatile than the broader market. Comparatively, Omeros has a beta of 2.54, meaning that its share price is 154% more volatile than the broader market.

Omeros has a net margin of 0.00% compared to Akebia Therapeutics' net margin of -13.54%. Akebia Therapeutics' return on equity of -88.88% beat Omeros' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-13.54%	-88.88%	-7.74%
Omeros	N/A	-164.92%	69.41%

Summary

Omeros beats Akebia Therapeutics on 12 of the 16 factors compared between the two stocks.

How does Akebia Therapeutics compare to Geron?

Akebia Therapeutics (NASDAQ:AKBA) and Geron (NASDAQ:GERN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

Akebia Therapeutics has a beta of 0.26, indicating that its stock price is 74% less volatile than the broader market. Comparatively, Geron has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market.

Akebia Therapeutics has a net margin of -13.54% compared to Geron's net margin of -34.17%. Geron's return on equity of -24.48% beat Akebia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Akebia Therapeutics	-13.54%	-88.88%	-7.74%
Geron	-34.17%	-24.48%	-10.30%

Akebia Therapeutics presently has a consensus price target of $3.75, indicating a potential upside of 324.02%. Geron has a consensus price target of $4.00, indicating a potential upside of 172.11%. Given Akebia Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Akebia Therapeutics is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Akebia Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, Geron had 1 more articles in the media than Akebia Therapeutics. MarketBeat recorded 6 mentions for Geron and 5 mentions for Akebia Therapeutics. Geron's average media sentiment score of 0.72 beat Akebia Therapeutics' score of 0.18 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Akebia Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Geron	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Akebia Therapeutics has higher revenue and earnings than Geron. Geron is trading at a lower price-to-earnings ratio than Akebia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Akebia Therapeutics	$236.20M	1.04	-$5.34M	-$0.11	N/A
Geron	$183.88M	5.14	-$83.50M	-$0.11	N/A

33.9% of Akebia Therapeutics shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 4.3% of Akebia Therapeutics shares are owned by company insiders. Comparatively, 1.7% of Geron shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Akebia Therapeutics beats Geron on 9 of the 15 factors compared between the two stocks.

Get Akebia Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKBA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AKBA vs. The Competition

Export

Metric	Akebia Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$241.86M	$3.72B	$7.03B	$13.07B
Dividend Yield	N/A	3.69%	2.57%	10.65%
P/E Ratio	-8.04	10.77	271.26	25.40
Price / Sales	1.04	1,367.37	623.44	105.59
Price / Cash	N/A	101.42	75.70	53.27
Price / Book	9.83	16.78	12.92	6.21
Net Income	-$5.34M	-$13.32M	$3.45B	$347.71M
7 Day Performance	-2.80%	1.76%	1.16%	1.08%
1 Month Performance	-36.83%	2.86%	2.17%	1.87%
1 Year Performance	-72.79%	54.10%	62.38%	20.79%

Akebia Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AKBA Akebia Therapeutics	2.0154 of 5 stars	$0.88 +1.7%	$3.75 +324.0%	-72.8%	$241.86M	$236.20M	N/A	430
AVTX Avalo Therapeutics	2.5146 of 5 stars	$19.77 +7.9%	$45.10 +128.1%	+117.2%	$982.50M	$60K	N/A	40	News Coverage Analyst Upgrade Analyst Revision
SANA Sana Biotechnology	1.7678 of 5 stars	$3.61 +2.6%	$9.50 +163.2%	+6.6%	$979.59M	N/A	N/A	380	Trending News Earnings Report Analyst Forecast Analyst Revision
JANX Janux Therapeutics	2.6793 of 5 stars	$16.41 +3.5%	$37.58 +129.0%	-35.8%	$969.02M	$10M	N/A	30	News Coverage Analyst Revision
OMER Omeros	3.6685 of 5 stars	$13.62 +2.8%	$38.00 +179.0%	+289.8%	$958.97M	N/A	19.46	210	Trending News Earnings Report Analyst Upgrade Options Volume Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AKBA) was last updated on 8/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Akebia Therapeutics (AKBA) Competitors

AKBA vs. AVTX, SANA, JANX, OMER, and GERN

How does Akebia Therapeutics compare to Avalo Therapeutics?

Summary

How does Akebia Therapeutics compare to Sana Biotechnology?

Summary

How does Akebia Therapeutics compare to Janux Therapeutics?

Summary

How does Akebia Therapeutics compare to Omeros?

Summary

How does Akebia Therapeutics compare to Geron?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA vs. The Competition

Akebia Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Akebia Therapeutics (AKBA) Competitors

AKBA vs. AVTX, SANA, JANX, OMER, and GERN

How does Akebia Therapeutics compare to Avalo Therapeutics?

Do analysts rate AVTX or AKBA?

Does the media refer more to AVTX or AKBA?

Which has more risk & volatility, AVTX or AKBA?

Is AVTX or AKBA more profitable?

Do institutionals & insiders have more ownership in AVTX or AKBA?

Which has better earnings & valuation, AVTX or AKBA?

Summary

How does Akebia Therapeutics compare to Sana Biotechnology?

Does the media prefer AKBA or SANA?

Which has preferable earnings and valuation, AKBA or SANA?

Is AKBA or SANA more profitable?

Do analysts prefer AKBA or SANA?

Which has more risk & volatility, AKBA or SANA?

Do institutionals and insiders believe in AKBA or SANA?

Summary

How does Akebia Therapeutics compare to Janux Therapeutics?

Do analysts prefer JANX or AKBA?

Is JANX or AKBA more profitable?

Do institutionals & insiders hold more shares of JANX or AKBA?

Which has preferable earnings and valuation, JANX or AKBA?

Does the media refer more to JANX or AKBA?

Which has more risk and volatility, JANX or AKBA?

Summary

How does Akebia Therapeutics compare to Omeros?

Does the media prefer AKBA or OMER?

Which has better earnings & valuation, AKBA or OMER?

Do analysts rate AKBA or OMER?

Do insiders and institutionals have more ownership in AKBA or OMER?

Which has more risk and volatility, AKBA or OMER?

Is AKBA or OMER more profitable?

Summary

How does Akebia Therapeutics compare to Geron?

Which has more volatility & risk, AKBA or GERN?

Is AKBA or GERN more profitable?

Do analysts prefer AKBA or GERN?

Does the media refer more to AKBA or GERN?

Which has better valuation and earnings, AKBA or GERN?

Do institutionals & insiders have more ownership in AKBA or GERN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AKBA vs. The Competition

Akebia Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools